Concentric Medical Announces Product and Procedure Reimbursement as Well as Full Commercialization of the Merci Retriever® in Japan
MOUNTAIN VIEW, Calif., Oct. 4 /PRNewswire/ -- Concentric Medical, Inc., the global leader in devices for clot removal in ischemic stroke patients, today announced that the Merci Retriever® has recently received both product and procedure reimbursement from the Japanese Ministry of Health, Labor and Welfare. The Merci Retriever is a catheter-based medical device that physicians at stroke centers use to remove blood clots from the brains of patients suffering an ischemic stroke.
On May 4th, Concentric Medical announced the Shonin approval of the Merci Retriever®, Merci® Microcatheter, and Merci® Balloon Guide Catheter.
Nobuyuki Sakai, M.D., D.M.Sc., Director, Neurosurgery & Stroke Center at Kobe City General Hospital said, "The Merci Retriever is quickly becoming a very meaningful treatment option for acute stroke patients in Japan. The initial cases at leading stroke institutions since Shonin approval have been very successful. Reimbursement for the Merci Retriever and the mechanical procedure are a critical part of making the Merci system available to all neurosurgeons, neurologists, and hospitals in Japan that treat acute stroke patients."
Century Medical, Inc. is the exclusive distribution partner for Concentric Medical in Japan. The two companies worked together to obtain both Shonin approval and reimbursement for the Merci Retriever, which is the first device for clot removal for ischemic patients to be approved in Japan.
One of Concentric Medical's strategic objectives has been global expansion. The incidence of stroke and the mortality and disability associated with stroke are very significant issues for health care systems across the world. Maria Sainz, President and CEO of Concentric Medical said, "We are honored to be the first to offer a device solution for stroke patients in Japan. Launching the Merci system in Japan is a very significant milestone and a great new